Drug screening method for the treatment of brain damage
OwnerMingjie Zhang, Nikolaus Sucherinventors
Life of this patent
Estimating the term…
Abstract
NMR spectroscopy is used as an efficient and effective rapid screening method for identifying compounds that interact with PSD-95. This method includes the steps of taking a first NMR spectrum of a sample of free PDZ2; mixing a test compound with said sample of free PDZ2 to form a test sample; taking a second NMR spectrum of said test sample; and comparing said first and second spectra. An observable difference of the two spectra indicates that the test sample contains ingredient(s) capable of binding to the PDZ domains of PSD-95.
Claims22
A method of screening for compounds comprising the steps of
- a) obtaining a sample of free Postsynaptic density-95 protein;
- b) taking a first NMR spectrum of the free PDZ domain of said free Postsynaptic density-95 protein;
- c) adding a test compound into said sample of free Postsynaptic density-95 protein to form a test sample;
- d) incubating said test compound with said PDZ domain to allow binding reaction;
- e) taking a second NMR spectrum of said incubated PDZ domain;
- f) comparing said first and second NMR spectra wherein binding reaction is identified.
A method of treatment of brain damage in humans resulting from hypoxic or ischemic insults comprising administering an effective dose of baicalin, oroxylin A-glucuronide (oroxyloside), wogonoside or nor-wogonoside.
A pharmaceutical composition comprising a substantially pure form of at least one flavanoid selected from a group comprising baicalin, oroxylin A-glucuronide (oroxyloside), wogonoside and nor-wogonoside.
A method of screening for compounds comprising the steps of
- obtaining a sample comprising the PDZ-2 domain of Post-synaptic density 95 protein;
- taking a first NMR spectrum of said PDZ-2 domain of Post-synaptic density 95 protein;
- adding a test compound into said sample comprising the PDZ domain of Post-synaptic density 95 protein to form a test sample;
- incubating said test compound with said PDZ domain to allow a binding reaction;
- taking a second NMR spectrum of said incubated PDZ domain;
- and
- comparing said first and second NMR spectra wherein said binding reaction is identified.
Dependencies are inferred from the claim text.